Key facts
- Notable investors include FountainBridge Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Luofang Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Luofang Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Luofang Bio
Manufacturer of innovative polymer-based pharmaceuticals intended to develop first-in-class therapies for chronic conditions. The company offers AI-driven molecular design, automated synthesis and screening, organ-on-chip validation, and advanced structural analysis, enabling patients with cardiovascular, autoimmune, metabolic, and allergic diseases to access safe and effective long-term treatments.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2025
- Website
- polyncure.com/
- Ownership
- Privately Held (backing)
Luofang Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Luofang Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Luofang Bio in its N-PORT filings yet. We sweep new filings monthly.